Intranasal administration of recombinant TRAIL down-regulates CXCL-1/KC in an ovalbumin-induced airway inflammation murine model

Veronica Tisato; Chiara Garrovo; Stefania Biffi; Francesca Petrera; Rebecca Voltan; Fabio Casciano; Germana Meroni; Chiara Agnoletto; Giorgio Zauli; Paola Secchiero

doi:10.1371/journal.pone.0115387

Intranasal administration of recombinant TRAIL down-regulates CXCL-1/KC in an ovalbumin-induced airway inflammation murine model

PLoS One. 2014 Dec 15;9(12):e115387. doi: 10.1371/journal.pone.0115387. eCollection 2014.

Affiliations

¹ Department of Morphology, Surgery, Experimental Medicine and LTTA Centre, University of Ferrara, Ferrara, Italy.
² Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy.
³ Cluster in Biomedicine, CBM S.c.r.l., Area Science Park, Trieste, Italy.

Abstract

Ovalbumin (OVA)-sensitized BALB/c mice were i.n. instilled with recombinant TNF-related apoptosis inducing ligand (TRAIL) 24 hours before OVA challenge. The total number of leukocytes and the levels of the chemokine CXCL-1/KC significantly increased in the bronchoalveolar lavage (BAL) fluids of allergic animals with respect to control littermates, but not in the BAL of mice i.n. pretreated with recombinant TRAIL before OVA challenge. In particular, TRAIL pretreatment significantly reduced the BAL percentage of both eosinophils and neutrophils. On the other hand, when TRAIL was administrated simultaneously to OVA challenge its effect on BAL infiltration was attenuated. Overall, the results show that the i.n. pretreatment with TRAIL down-modulated allergic airway inflammation.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Administration, Intranasal
Allergens / immunology
Animals
Chemokine CXCL1 / genetics
Chemokine CXCL1 / metabolism*
Disease Models, Animal
Down-Regulation
Female
Mice
Ovalbumin / immunology
Pneumonia / drug therapy*
Pneumonia / immunology
Recombinant Proteins / administration & dosage
Respiratory System / drug effects
Respiratory System / immunology
TNF-Related Apoptosis-Inducing Ligand / administration & dosage
TNF-Related Apoptosis-Inducing Ligand / genetics
TNF-Related Apoptosis-Inducing Ligand / pharmacology*
TNF-Related Apoptosis-Inducing Ligand / therapeutic use

Substances

Allergens
Chemokine CXCL1
Recombinant Proteins
TNF-Related Apoptosis-Inducing Ligand
Ovalbumin

Grants and funding

This study was supported by a grant from Italian Ministry of Health (GR-2010-2310832) to VT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.